返回
返回
返回
HeYuan Bio and Shanghai Li Ji have jointly established a joint venture to continuously empower the life sciences sector.
On February 17, 2023, Heyuan Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Heyuan Bio”) and Shanghai Liji Biotechnology Co., Ltd. (hereinafter referred to as “Shanghai Liji”) signed a strategic cooperation agreement to jointly establish Heyuan Liji (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Heyuan Liji”).
At the signing ceremony, Pan Oudong, Chairman of HeYuan Bio, and Jia Guodong, General Manager, each outlined the strategic objectives and future vision for this collaboration. Wang Fujie, Deputy General Manager of HeYuan Bio, and Li Ruibiao, Founder of Shanghai Li Ji Bio, formally signed the cooperation agreement on site.
Strategic Cooperation Agreement Signed with Yuanli Jiji
HeYuan Li Ji will take over the well‑known local “Li Ji Bio” reagent brand, focusing on the life sciences and biotechnology sectors. It will offer customers cutting‑edge, ready‑to‑use, user‑friendly, and cost‑effective products, including reagents and assay kits for molecular biology, immunology, biochemistry, and cell biology. With the comprehensive support of HeYuan Bio, it will continuously strengthen its capabilities in the innovative research and development of high‑quality life science reagents, consistently delivering premium products to the industry and enhancing R&D efficiency.
Li Ruibiao, founder of “Li Ji Bio,” stated: “HeYuan Bio is a leading publicly listed company in the fields of genetic research and gene therapy, offering integrated CRO and CDMO services. We are honored to have jointly established HeYuan Li Ji through a joint venture with HeYuan Bio. Looking ahead, we hope that, empowered by HeYuan Bio’s robust R&D capabilities, market‑expansion expertise, and strategic business deployment, both parties will fully leverage our respective strengths to serve the life sciences sector and create greater value.”
Wang Fujie, Deputy General Manager of HeYuan Bio, stated: “Shanghai Li Ji has demonstrated proactive leadership in the localized development and innovation of life science reagents. HeYuan Bio places great emphasis on industrial integration and indigenous innovation. The establishment of HeYuan Li Ji represents another step in empowering industry growth, as well as a significant move to actively implement the company’s sustainable development strategy and explore synergies across the upstream and downstream segments of the value chain. We wish HeYuan Li Ji, through the joint efforts of both parties, to serve an expanding base of customers and contribute to the continuous enhancement of China’s overall competitiveness in the life sciences and biopharmaceutical sectors.”
As a biotechnology company focused on the gene therapy field, HeYuan Bio specializes in providing CRO services—including the development of gene‑therapy vectors and gene‑function studies—for basic research in gene therapy. It also offers CDMO services—such as process development and testing, IND‑CMC pharmaceutical studies, and GMP‑compliant clinical‑sample production—for the R&D of gene‑therapy products, including recombinant viral vector therapeutics, oncolytic viruses, and CAR‑T cell therapies. To date, the company has served over 8,000 research groups and more than 150 gene‑ and cell‑therapy CDMO projects, helping clients secure 20 clinical trial approvals across multiple countries, including China and the United States.
With the mission of “Empowering Gene Therapy, Safeguarding Life and Health,” and centered on the research, development, and manufacturing of gene‑therapy vectors, HeYuan Bio remains committed to a customer‑first approach and to delivering expert services. The company aims to become an internationally leading CXO group in the fields of gene and cell therapy, accelerating basic research, drug discovery, pharmaceutical studies, clinical development, and commercialization, thereby driving the advancement of the gene‑therapy industry and benefiting human health.
Group Website
-
Contact Information
Landline phone:021-50778506
Business Manager:18616108315Business Cooperation/Scholarships:18616108697
Address:4th Floor, Building 27, Lane 908, Ziping Road, International Medical Park, Pudong New Area, Shanghai
Email:ztt0005@obiosh.com
WeChat Official Account
Online Customer Service 1
Online Customer Service 2
Telephone consultation
